Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34,358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer.
Shi Y, Jiang Y, Pan B, Wang Z, Li H, Ma Y, Liu Y, He K, Wang Z, Lu J, Shi M, Shen B, Zhou G, Yin R, Rossi A, Ito K, Santarpia M, Um SW, Wang X, Chen C, Feng J. Shi Y, et al. Among authors: shi m. Transl Lung Cancer Res. 2022 May;11(5):817-831. doi: 10.21037/tlcr-22-315. Transl Lung Cancer Res. 2022. PMID: 35693279 Free PMC article.
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y, Ji M, Jiang Y, Yin R, Wang Z, Li H, Wang S, He K, Ma Y, Wang Z, Lu J, Shi M, Shen B, Zhou G, Leong TL, Wang X, Chen C, Feng J. Shi Y, et al. Among authors: shi m. Transl Lung Cancer Res. 2022 Jun;11(6):1051-1068. doi: 10.21037/tlcr-22-350. Transl Lung Cancer Res. 2022. PMID: 35832459 Free PMC article.
Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study.
Jiang Y, Shi Y, Liu Y, Wang Z, Ma Y, Shi X, Lu L, Wang Z, Li H, Zhang Y, Liu C, Zhang S, Zhong Z, Lu J, Shi M, Shen B, Zhou G, Yin R, Galetta D, Grenda A, Romero A, Hughes BGM, Chen C, Wang X, Feng J. Jiang Y, et al. Among authors: shi m, shi y, shi x. Transl Lung Cancer Res. 2022 Dec;11(12):2521-2538. doi: 10.21037/tlcr-22-857. Transl Lung Cancer Res. 2022. PMID: 36636415 Free PMC article.
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review.
Ma Y, Shi X, Zhao K, Hu S, Shi Y, Jiang Y, Liu Y, Lu L, Chang Y, Zhou F, Dai Y, Wu Z, Li S, Qian Z, Xu X, Li C, Shen B, Zhou G, Chen C, Wang X, Feng J. Ma Y, et al. Among authors: shi y, shi x. Front Oncol. 2024 Mar 28;14:1328844. doi: 10.3389/fonc.2024.1328844. eCollection 2024. Front Oncol. 2024. PMID: 38606104 Free PMC article.
34,358 results
You have reached the last available page of results. Please see the User Guide for more information.